NEFL, neurofilament light, 4747

N. diseases: 247; N. variants: 26
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Traditional and net meta-analyses were performed based on 42 studies that tested the diagnostic performance of neurofilament light chain protein (NfL) concentration in CSF and serum/plasma from patients with neurodegenerative dementia. 31026486 2019
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Plasma neurofilament light chain (NfL) is one of the established biomarkers of AD, suggesting that it may be useful as an indicator of dementia in DS patients. 30951523 2019
CUI: C0497327
Disease: Dementia
Dementia
0.100 AlteredExpression disease BEFREE To investigate cerebrospinal fluid (CSF) levels of neurofilament light (NFL) protein, a marker of neuroaxonal degeneration, in control participants and patients with dementia, motor neuron disease, and parkinsonian disorders (determined by clinical criteria and autopsy), and determine its association with longitudinal cognitive decline. 30508027 2019
CUI: C0497327
Disease: Dementia
Dementia
0.100 AlteredExpression disease BEFREE The NfL level was increased at baseline in patients with mild cognitive impairment and AD dementia (mean levels: cognitive unimpairment, 32.1 ng/L; mild cognitive impairment, 37.9 ng/L; and AD dementia, 45.9 ng/L; P < .001) and increased in all diagnostic groups, with the greatest increase in patients with AD dementia. 31009028 2019
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE YKL-40, neopterin, and the axonal marker neurofilament light protein (NFL) were analyzed with ELISA in archived CSF samples from 120 HIV-infected individuals (85 untreated neuroasymptomatic patients, 7 with HIV-associated dementia, and 28 on effective ART) and 39 HIV-negative controls. 30678707 2019
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE We evaluated CSF amyloid-β (Aβ)42 and Aβ40, total (t)-tau, phosphorylated (p)-tau, total prion protein (t-PrP), and neurofilament light chain protein (NfL) in healthy controls (n = 50) and subjects with iNPH (n = 71), Alzheimer's disease (AD) (n = 60), and several other subtypes of dementia (n = 145). 30883350 2019
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE We analyzed 5 validated pathophysiological cerebrospinal fluid biomarkers (Aβ<sub>1-42</sub>, t-tau, p-tau<sub>181</sub>, NFL, YKL-40) in 113 participants (healthy controls [N = 20], subjective memory complainers [N = 36], mild cognitive impairment [N = 20], and AD dementia [N = 37], age: 66.7 ± 10.4, 70.4 ± 7.7, 71.7 ± 8.4, 76.2 ± 3.5 years [mean ± SD], respectively) using Density-Based Spatial Clustering of Applications with Noise, which does not require a priori determination of the number of clusters. 31585366 2019
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Finally, NfL concentration may be the most suitable biomarker for dementia progression in DS. 30902060 2019
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE NF-L is a biomarker for neurodegeneration in DS with potential for use in future clinical trials to prevent or delay dementia. 29631614 2018
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE We used immunoassays to measure conventional CSF markers of amyloid and tau pathology (amyloid beta (Aβ)1-42, total tau (T-tau), and phosphorylated tau (P-tau)) as well as amyloid processing (AβX-38, AβX-40, AβX-42, soluble amyloid precursor protein (sAPP)α, and sAPPβ), large fibre axonal degeneration (neurofilament light chain (NFL)), and neuroinflammation (YKL-40) in 245 patients with a variety of dementias and 30 controls. 29558979 2018
CUI: C0497327
Disease: Dementia
Dementia
0.100 AlteredExpression disease BEFREE Despite p-tau/Aβ<sub>42</sub> and Aβ<sub>42</sub>/Aβ<sub>40</sub> levels comparable to those of the AD-Dementia group, mismatches had significantly lower levels of NFL and total tau. 29959263 2018
CUI: C0497327
Disease: Dementia
Dementia
0.100 AlteredExpression disease BEFREE Increased NFL levels are a common feature in neurodegenerative dementias. 29391125 2018
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE In this prospective case-control study, an ultrasensitive assay was used to measure plasma NFL concentration in 193 cognitively healthy controls, 197 patients with mild cognitive impairment (MCI), and 180 patients with AD dementia from the Alzheimer's Disease Neuroimaging Initiative. 28346578 2017
CUI: C0497327
Disease: Dementia
Dementia
0.100 Biomarker disease BEFREE Our results suggest that plasma NFL levels may not be a useful biomarker for the diagnosis of prodromal and dementia stages of AD. 28428015 2017